Hydrogen Sulfide and Cell Signaling

Annual Review of Pharmacology and Toxicology - Tập 51 Số 1 - Trang 169-187 - 2011
Ling Li1, Peter Rose2, Philip K. Moore3,2
1Section of Inflammation and Signal Transduction, Division of Immunology and Inflammation, Imperial College London, London W12 0NN, United Kingdom
2Pharmaceutical Science Division, King's College London, London SE1 9NH, United Kingdom
3Current address: Departments of Pharmacology and Pharmacy, National University of Singapore, Singapore 117597;

Tóm tắt

Hydrogen sulfide (H2S) is a gaseous mediator synthesized from cysteine by cystathionine γ lyase (CSE) and other naturally occurring enzymes. Pharmacological experiments using H2S donors and genetic experiments using CSE knockout mice suggest important roles for this vasodilator gas in the regulation of blood vessel caliber, cardiac response to ischemia/reperfusion injury, and inflammation. That H2S inhibits cytochrome c oxidase and reduces cell energy production has been known for many decades, but more recently, a number of additional pharmacological targets for this gas have been identified. H2S activates KATP and transient receptor potential (TRP) channels but usually inhibits big conductance Ca2+-sensitive K+ (BKCa) channels, T-type calcium channels, and M-type calcium channels. H2S may inhibit or activate NF-κB nuclear translocation while affecting the activity of numerous kinases including p38 mitogen-activated protein kinase (p38 MAPK), extracellular signal-regulated kinase (ERK), and Akt. These disparate effects may be secondary to the well-known reducing activity of H2S and/or its ability to promote sulfhydration of protein cysteine moieties within the cell.

Từ khóa


Tài liệu tham khảo

10.1517/13543770902858824

10.1002/cbf.1618

10.1038/ki.2009.221

10.1042/BST0351375

10.1016/j.freeradbiomed.2009.09.018

10.1097/CCM.0b013e3181cab0ee

7. Kimura H. 2010. Hydrogen sulfide: its production, release and functions. Amino Acids. In press, doi:10.1007/s00726-010-0510-x

10.1152/japplphysiol.00793.2005

10.1016/j.pharmthera.2009.05.005

10.1016/j.tips.2007.11.003

10.1089/ars.2009.2885

10.1242/jeb.010066

10.1016/j.neuint.2007.05.016

10.1038/nrd2425

10.1111/j.1582-4934.2009.00645.x

10.1089/ars.2008.2132

17. Stipanuk MH, Ueki I. 2010. Dealing with methionine/homocysteine sulfur: cysteine metabolism to taurine and inorganic sulfur. J. Inherit. Metab. Dis. In press, doi:10.1007/s10545-009-9006-9

10.1111/j.1471-4159.2004.02617.x

10.1007/s00726-007-0011-8

10.1016/j.bbrc.2003.11.130

10.1093/emboj/20.21.6008

10.1006/bbrc.1997.6878

10.1038/sj.bjp.0706906

10.1007/s10787-007-1590-4

10.1152/ajpheart.00331.2004

10.1016/j.ejphar.2006.02.001

10.1073/pnas.0807974105

10.1152/ajpgi.90484.2008

10.1124/jpet.107.133538

10.1016/j.cardiores.2007.05.026

10.1016/j.freeradbiomed.2006.12.011

10.1161/CIRCULATIONAHA.107.753467

10.1016/S0006-291X(03)00256-0

10.1016/j.bbrc.2006.04.162

10.1097/00004872-200310000-00015

10.1016/j.bbrc.2003.11.081

10.1126/science.1162667

10.1073/pnas.0908047106

10.1161/CIRCULATIONAHA.108.843979

10.1152/ajpheart.00088.2007

10.1291/hypres.31.1619

10.1161/ATVBAHA.108.179333

10.1016/j.ejphar.2006.12.011

10.1096/fj.06-6270fje

10.1152/ajplung.00489.2005

10.1152/japplphysiol.00096.2006

10.1073/pnas.0705891104

10.1097/01.shk.0000225722.56681.64

10.1096/fj.04-3583fje

10.1096/fj.04-3023fje

10.1038/sj.bjp.0706014

10.1053/j.gastro.2006.11.042

10.1089/ars.2009.2899

10.1038/sj.bjp.0707193

10.1096/fj.07-8669com

10.1242/jeb.02480

10.1152/ajpregu.90566.2008

10.1152/ajpregu.00025.2008

10.1016/j.jchromb.2009.05.026

10.1016/j.niox.2009.07.002

10.1093/annhyg/34.3.323

10.1007/s10863-008-9166-6

10.1016/j.lfs.2008.08.006

10.1002/hep.20817

10.1159/000260073

10.1124/jpet.105.091595

10.1016/j.exer.2008.09.011

10.1254/jphs.SC0070199

10.1016/j.ejphar.2009.11.024

10.1089/ars.2009.2894

10.1126/scisignal.2000464

10.1139/Y07-120

10.1016/j.ejphar.2008.03.044

10.1007/s00395-005-0569-9

10.1053/j.gastro.2005.07.060

10.1016/j.neuroscience.2007.12.008

10.1007/978-90-481-2259-2_7

10.1007/s00424-009-0737-0

10.1093/cvr/cvn140

10.1136/gut.2007.144543

10.4149/gpb_2009_02_190

10.1016/j.eururo.2007.10.024

10.1038/sj.bjp.0706277

10.1016/j.freeradbiomed.2006.03.021

10.1016/j.neurobiolaging.2009.06.001

10.1097/MPA.0b013e31816857bb

10.1038/labinvest.2008.73

Jin HF, 2008, Zhonghua Xin Xue Guan Bing Za Zhi, 36, 541

10.1073/pnas.0705710104

10.1189/jlb.1006599

10.3181/0904-RM-137

10.1016/j.freeradbiomed.2009.04.014

10.1111/j.1749-6632.2009.04911.x

10.1161/CIRCRESAHA.109.199919

10.1091/mbc.E09-03-0199

10.1007/s00380-003-0743-7

10.1510/icvts.2009.219535

10.1038/labinvest.3700391

10.1111/j.1471-4159.2006.04283.x

10.1038/labinvest.2009.61

10.1096/fj.04-2279fje

10.1096/fj.05-4712fje

10.1016/j.tox.2007.07.020

10.1152/ajpheart.01111.2007

10.1016/j.bbrc.2006.05.002

10.1042/CBI20090368

10.1089/ars.2009.2945

10.1152/ajpheart.00244.2008

10.1096/fj.04-1815fje

10.1089/ars.2006.8.661

10.1089/ars.2008.2282

10.1038/sj.bjp.0707540

10.1152/ajpheart.00377.2008

10.1211/jpp.61.02.0010

10.1152/ajprenal.00145.2009

10.1089/ars.2008.2073

10.1016/j.bbrc.2006.10.058

10.1016/j.freeradbiomed.2008.11.018

10.1016/j.bmcl.2009.02.007

10.1167/iovs.09-3999

10.1111/j.1471-4159.2010.06580.x